Investing & Markets

Make better decisions with investing tips, technical analysis, market commentary, and more

Personal Finance

Make more, save more, spend smarter, and keep more of what you earn

Business News

Stock market news & analysis


Positive Stem Cells Safety Profile (STEM, GERN, NBS, OPXA)

By BioHealth Investor on 05/03/2010 – 10:05 am PDTLeave a Comment

StemCells, Inc. (NASDAQ: STEM) has created some interest in the stem cell sector again on some important safety news.  While today’s news is best for StemCells, Inc. (NASDAQ: STEM) as a company, this will only act to highlight others involved in stem cell research.  We are also seeing moves in Geron Corporation (NASDAQ: GERN), Neostem, Inc. (AMEX: NBS), and Opexa Therapeutics, Inc. (NASDAQ: OPXA).

The company (StemCells) announced that Nathan Selden (M.D., Ph.D., F.A.C.S., F.A.A.P.) is presenting a feature presentation today at the American Association of Neurological Surgeons 2010 Annual Meeting.  This is said to be one of the leading forums for neurosurgeons from around the world to present and discuss cutting-edge research in the field.

Dr. Selden was co-principal investigator of StemCells’ Phase I clinical trial in neuronal ceroid lipofuscinosis (Batten disease), a fatal neurodegenerative disorder in children, where he presents the positive safety data from the trial and will note that additional data from the ongoing long-term follow-up study continue to affirm the safety profile of the Company’s HuCNS-SC cells.  He notes, …“Initial results regarding safety associated with the transplantation of a significant cell dose are certainly promising.  Further investigation of HuCNS-SC cells is warranted for infantile and late-infantile NCL, as well as for exploring this cell therapy approach for other conditions of the central nervous system.”

The Phase I NCL trial was the first ever FDA-authorized clinical trial to use purified human neural stem cells as a potential therapeutic agent.  That study was designed primarily to evaluate the safety of the Company’s HuCNS-SC product candidate

Related Articles:

  1. StemCells Scores New Stem Cell Patent (STEM)
  2. Stem Cells Versus Aging, Fountain of Youth (BTIM, GERN, ACTC)
  3. FDA response for ACT anticipated on January 31 (NASDAQ:ACTC)
  4. Ziopharm Shows Positive Results (NASDAQ:ZIOP)
  5. Geron Will Re-initiate Clinical Trials (NASDAQ:GERN)

Pages: 1 2

Comments are closed.